Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
暂无分享，去创建一个
[1] R. Guillevin,et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.
[2] M. Moschovi,et al. Malignant Progression of a Pleomorphic Xanthoastrocytoma in a Child , 2010, Neuropediatrics.
[3] A. Brandes,et al. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference , 2010, BMC Cancer.
[4] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[5] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[6] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[7] D. Brat,et al. Pleomorphic xanthoastrocytoma , 1999, Cancer.
[8] P. Pahapill,et al. Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. , 1996, Neurosurgery.
[9] S. Tsutsumi,et al. Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report. , 2010, Neurologia medico-chirurgica.